BioLineRX
BLRX
28 hedge funds and large institutions have $33.1M invested in BioLineRX in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 28 → 28 (0)
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
19% less capital invested
Capital invested by funds: $40.9M → $33.1M (-$7.85M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$803K |
| 2 |
Morgan Stanley
New York
|
+$84.6K |
| 3 |
VF
Virtu Financial
New York
|
+$72.3K |
| 4 |
MCC
Malaga Cove Capital
Pv Estates,
California
|
+$50.2K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$35.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$215K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$186K |
| 3 |
Millennium Management
New York
|
-$95K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$48K |
| 5 |
JP Morgan Chase
New York
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $2K | +$1.84K | +3 | New |
|
|
FMA
27
FNY Managed Accounts
New York
| $1K | -$613 | -1 | -25% |
|
|
KF
28
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
|
RE
29
RBC Europe
London,
United Kingdom
| $174 | – | – | – |
|
|
30
Millennium Management
New York
| – | -$95K | -145 | Closed |
|
|
31
UBS Group
Zurich,
Switzerland
| – | -$48K | -74 | Closed |
|
|
32
JP Morgan Chase
New York
| – | -$31K | -48 | Closed |
|
|
OAM
33
Oxford Asset Management
Oxford,
United Kingdom
| – | -$25K | -38 | Closed |
|
|
AIC
34
Aurora Investment Counsel
Atlanta,
Georgia
| – | -$16K | -24 | Closed |
|
BLRX Hedge Fund Activity: Q1 2018 in Review
28 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2018, worth a combined $33.1M — down 19% from $40.9M a quarter earlier.
Fund positioning in BLRX was balanced in Q1 2018: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 7 trimmed.
The largest buyer was DZ Bank, opening a new position worth an estimated $803K. The largest seller was Renaissance Technologies, cutting an estimated $215K.
- 28 institutional investors held BioLineRX (BLRX) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $33.1M of BioLineRX stock for Q1 2018, down 19% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q1 2018 and 5 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q1 2018 was DZ Bank, an estimated $803K added.
- The largest BioLineRX seller in Q1 2018 was Renaissance Technologies, an estimated $215K sold.
Based on aggregated 13F filings for Q1 2018.